uniQure Stock Soars as FDA's Vinay Prasad Exit Sparks Analyst Upgrades
uniQure stock jumps after Wells Fargo ($60 PT) and RBC ($35 PT) upgrades, driven by Vinay Prasad's FDA exit boosting AMT-130 Huntington's gene therapy outlook.
Already have an account? Sign in.